2024-10-24 11:09:32 :
Piramal Pharma Second Quarter Results Live Release: Piramal Pharma announced its second quarter results on October 23, 2024, demonstrating strong financial results. The company’s revenue increased significantly by 17.28% year-on-year, and profits soared an impressive 350% during the same period.
Compared with the previous quarter, Piramal Pharma’s revenue increased by 14.89%, and its profit increased significantly by 125.49%. This quarter’s results demonstrate the company’s effective operating strategy and market positioning.
It is worth noting that although selling, general and administrative (SG&A) expenses increased by 8.43% year-on-year, they fell by 3.48% month-on-month, reflecting the company’s emphasis on cost management during its growth process.
Operating income also showed considerable growth, with a month-on-month increase of 41.83% and a year-on-year increase of 21.27%. The operating performance was solid. Second quarter earnings per share (EPS) were $0.17, a significant year-on-year increase of 325%.
Despite a slight drop of -6.19% last week, Piramal Pharma has returned 57.11% and 57% over the past six months and year-to-date, respectively. Currently, the company’s market capitalization is $28,770.91 Cr, 52-week high $243.99 and lowest price $87.5.
As of October 24, 2024, Piramal Pharma’s outlook appears positive, with three out of five analysts giving it a Buy rating and two recommending a Strong Buy. The consensus recommendation remains a Strong Buy, reflecting confidence in the company’s future performance.
Piramal Pharmaceuticals Financials
| period | Q2 | Q1 | month-on-month growth | Q2 | year-on-year growth |
|---|---|---|---|---|---|
| total revenue | 2241.75 | 1951.14 | +14.89% | 1911.38 | +17.28% |
| Total Selling/General/Administrative Expenses | 559.53 | 579.69 | -3.48% | 516.03 | +8.43% |
| Depreciation/Amortization | 192.22 | 184.55 | +4.16% | 184.51 | +4.18% |
| total operating expenses | 1487.11 | 1419.07 | +4.79% | 1289.08 | +15.36% |
| operating income | 754.64 | 532.07 | +41.83% | 622.3 | +21.27% |
| net income before tax | 120.12 | -45.08 | +366.46% | 39.56 | +203.64% |
| net income | 22.59 | -88.64 | +125.49% | 5.02 | +350% |
| Diluted normalized earnings per share | 0.17 | -0.67 | +125.37% | 0.04 | +325% |
Follow us On Social Media   Twitter/X
